GKGoran Koracevic

Goran Koracevic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Goran Koracevic has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluating Mean Blood Pressure as a Potential Therapeutic Target in Systolic Hypertension with Too Low Baseline Diastolic Blood Pressure

    by Goran Koraćević, Milovan Stojanović

    Introduction: Isolated systolic hypertension (ISH) has a high mortality rate and a high prevalence of hypertension-mediated organ damage (HMODs). The aims of this paper are: (1) to search arterial hypertension (HTN) guidelines to determine whether mean blood pressure (BP) is mentioned as a treatment target for ISH patients with too-low pre-treatment dBP, and (2) to analyze whether there is a rationale for suggesting mean BP as a potential antihypertensive treatment target. Methods: We performed a search for HTN guidelines in Scopus, the Medline database, Springer Nature, Cambridge University Press, Oxford University Press, and Wiley-Blackwell. The scholarly search engine Google Scholar was also used. Results: Mean BP is already used to guide BP treatment in numerous settings, mostly in intensive care units, and guidelines recognize that mean BP can be used in several clinical scenarios to evaluate antihypertensive treatment. However, mean BP is not mentioned in half of the guidelines, and none of the 40 HTN guidelines mention mean BP as a chronic treatment target in ISH. Discussion: The main finding of this narrative review is that the problem of ISH with a too-low baseline dBP has been clearly identified but remains unresolved. This paper does not offer a definitive answer but presents an initial approach to addressing the problem. Conclusion: The problem of ISH with too-low dBP is clinically relevant, and such patients are difficult to treat. We propose mean BP for investigation and evaluation as a means of adjusting the intensity of antihypertensive treatment in large patient populations with ISH and too-low dBP.

  • Open Access

    Epistaxis Associated with Very High Blood Pressure: A Narrative Review of Guideline Classification and Management Considerations

    by Goran Koracevic, Emilija Živković Marinković, Sladjana Sibinčić, Milovan Stojanovic, Dragan Lović, Miloš Zdravković, Dragan Djordjević, Ruzica Tomasevic Jankovic

    Epistaxis is bleeding originating from the nostrils, nasal cavity, or nasopharynx, and affects nearly 60% of the general population at least once during their lifetime. The aim of this review is to analyze specific aspects of epistaxis associated with very high blood pressure. The need for dual management, involving both emergency/cardiologic assessment and ear, nose, and throat treatment, represents a specific feature of epistaxis associated with very high blood pressure. A lack of agreement among hypertension guidelines regarding the classification of epistaxis is evident, with some guidelines classifying it as a hypertensive emergency (HTN-E) and others as a hypertensive urgency (HTN-U). Furthermore, therapy recommended for very high blood pressure associated with epistaxis is seldom specified. This uncertainty supports a cautious approach to diuretic use. In addition, epistaxis may be challenging to manage in the subsequent days because blood pressure changes during this period are difficult to predict. From a practical perspective, it seems appropriate to treat the majority of patients with high blood pressure and epistaxis as having HTN-U, since epistaxis is rarely life-threatening and typically does not require hospitalization.

  • Open Access

    CAN WE IMPROVE GRAFT ACCEPTANCE BY SWITCHING TO VASODILATING BETA BLOCKERS INSTEAD OF NON-VASODILATING?

    by Goran Koraćević, Dimitrije Pavlović, Slađana Mićić, Marija Zdravković, Milan Đorđević, Miloš Zdravković, Dragan Lović, Dragan Đorđević, Maja Koraćević

    Beta blockers (BBs) are very important medications with numerous indications. They have been considered highly useful in the treatment of arterial hypertension with comorbidities such as heart failure, coronary artery disease, and arrhythmias. The focus of this review is to analyze whether a BB already prescribed to a patient is the right choice, given that BBs differ significantly – for example in their vasodilatory versus vasoconstrictive properties. Searches were performed on 11/11/2024 with the following results. In PubMed, using the search terms "graft acceptance" and "beta adrenergic blocker" (or "graft acceptance" and "beta blocker") no articles were found. In SCOPUS for the combined search terms "graft acceptance" and "beta adrenergic blocker" (or "graft acceptance" and "beta blocker") also yielded no items . In the web based search engine Google Scholar two items were retrieved, but neither was directly related to the topic. The review highlights several important factors influencing graft acceptance, including infection and host- versus- graft reaction, and tissue perfusion. Differences among BBs also affect peripheral vascular resistance and flow; therefore, they may influence tissue perfusion including graft perfusion. This could have consequences for graft acceptance. It is worth investigating whether vasodilatory BBs and/or highly β1-AR selective BBs provide bet-ter protection in graft preservation for patients already receiving BB therapy. The pragmatic outcome of such an investigation may enable clinicians to eventually switch to specific BBs when preparing for elective operations involving tissue graft implantation.

  • Open Access

    Frank's sign and coronary artery disease: Myth or fact?

    by Željko Ilić, Milovan Stojanović, Goran Koračević, Nastasija Mladenović

    Introduction: Frank's sign is a diagonal earlobe crease proposed as a potential clinical marker of coronary artery disease. However, its diagnostic value remains debated. Objective: To determine the prevalence of Frank's sign in patients with confirmed coronary artery disease and assess its association with disease severity. Methodology: This cross-sectional study included 213 patients with confirmed coronary artery disease. We divided patients into three groups based on the presence of Frank's sign: no Frank's sign (n=77), unilateral Frank's sign (n=87), and bilateral Frank's sign (n=49). We analysed demographic characteristics, cardiovascular risk factors, coronary angiographic findings, treatment modality, and left ventricular ejection fraction. Results: Frank's sign was present in 136 patients (63.85%). Of these, 87 (63.97%) had a unilateral sign and 49 (36.03%) a bilateral sign. Patients without Frank's sign were significantly younger (p < 0.001), while arterial hypertension was significantly more common among patients with bilateral Frank's sign (100%; p = 0.037). Single-vessel coronary artery disease was more common in patients with unilateral Frank's sign. In contrast, multivessel disease was more common in patients without Frank's sign and those with bilateral Frank's sign (p < 0.001). Patients with bilateral Frank's sign were more likely to require surgical myocardial revascularisation than those in the other groups (61.22%; p = 0.035). Conclusion: Frank's sign was common among patients with coronary artery disease. Bilateral Frank's sign was associated with multivessel coronary artery disease, and these patients more frequently underwent surgical myocardial revascularisation. These findings suggest that Frank's sign may serve as a simple clinical marker of advanced coronary artery disease. However, further research is needed to define its prognostic value better.

  • Open Access

    Impact of the severity of obstructive sleep apnea-hypopnea syndrome on the quality of life and exercise tolerance in hypertensive patients

    by Milovan Stojanovic, Marina Deljanin-Ilic, Lidija Ristic, Zoran Stamenkovic, Goran Koracevic, Dejan Petrovic, Dejana Gojkovic, Jovana Kostic

    Background/Aim. Obstructive sleep apnea-hypopnea syndrome (OSAHS) is associated with impaired quality of life (QoL) and reduced exercise tolerance. The aim of the study was to determine whether the severity of OSAHS influences the QoL and exercise tolerance in patients with moderate to severe OSAHS and arterial hypertension. Methods. The study included 115 consecutive patients with arterial hypertension and either moderate [40 (34.78%)] or severe [75 (65.22%)] OSAHS. Exercise tolerance was assessed using the exercise stress test, while QoL was evaluated with the Short Form-36 (SF-36) questionnaire. Results. The groups under study did not differ significantly in terms of age (54.80 ? 8.91 vs. 53.55 ? 9.53, p = 0.494) or sex distribution [females: 11 (27.50%) vs. 13 (17.33%), p = 0.201]. A high prevalence of cardiovascular risk factors was observed in the study population. Patients with severe OSAHS had significantly higher body mass index and neck circumference. Obesity was also more frequent among patients with severe OSAHS. In addition, this group demonstrated significantly higher apnea-hypopnea index, desaturation index, and time spent with oxygen saturation below 90%. There were no statistically significant differences in either exercise tolerance or the SF-36 parameters between the groups. Furthermore, no significant correlations were observed between apnea-hypopnea index, exercise tolerance, and QoL parameters. Multivessel coronary artery disease was detected in two asymptomatic patients. Conclusion. Patients with OSAHS overall exhibit multiple cardiovascular risk factors and are characterized by reduced QoL and decreased exercise tolerance. No significant correlation was found between OSAHS severity and exercise tolerance and QoL. The detection of multivessel coronary artery disease in asymptomatic patients in the study underscores the clinical significance of screening for coronary heart disease in patients diagnosed with OSAHS.

  • Open Access

    Challenges in assessing cardiovascular risk in obstructive sleep apnea-hypopnea syndrome: Applicability of existing tools

    by Milovan Stojanovic, Marina Deljanin-Ilic, Lidija Ristic, Zoran Stamenkovic, Dejana Gojkovic, Goran Koracevic

    Background/Aim. Obstructive sleep apnea-hypopnea syndrome (OSAHS) is associated with an increased cardiovascular risk (CVR). The aim of this study was to examine CVR in hypertensive patients with OSAHS using the Systematic Coronary Risk Evaluation 2 (SCORE2), SCORE2- Diabetes, and American College of Cardiology/American Heart Association for atherosclerotic cardiovascular disease (ACC/AHA ASCVD) risk scores. Methods. Due to strict exclusion criteria, out of 410 consecutive OSAHS patients, 92 hypertensive patients with moderate or severe OSAHS were included in the study. All patients underwent CVR assessment using SCORE2, SCORE2-Diabetes, and ACC/AHA ASCVD risk scores. Additionally, all patients, except for seven individuals with extreme obesity (weight over 130 kg) who were unable to perform the test, underwent an exercise stress test, and six of them required further diagnostic assessment using stress echocardiography (three), computed tomography coronary angiography (two), and/or invasive coronary angiography (three). Results. The results showed a substantial burden of moderate to high CVR across all scores. Severe OSAHS was associated with a higher percentage of moderate to high CVR, particularly with the ACC/AHA ASCVD calculator. However, no significant correlation was found between the apnea-hypopnea index and CVR. Furthermore, in three patients, invasive coronary angiography showed multivessel disease requiring myocardial revascularization. Conclusion. General CVR calculators may inadequately represent the specific CVR in OSAHS patients, high-lighting the need for tailored risk assessment and increased screening for coronary artery disease in this population. Our results emphasize the clinical relevance of screening for coronary artery disease in individuals with OSAHS.


  • Uncontrolled arterial hypertension in the mirror of ethiopathogenetic, diagnostic and clinical aspects of the disease

    by Goran Koraćević, Slađana Mićić, Milovan Stojanović

    The term uncontrolled hypertension (UH) is commonly applied to all patients with hypertension (HTA) who do not achieve their target blood pressure (BP) for various reasons, which may include pseudoresistance or resistant HTA. Resistant HTA is defined as a BP reading exceeding 140/90 mmHg in the doctor’s office in patients who are on three or more antihypertensive medications, including diuretics, at optimal or maximally tolerated doses. Pseudoresistant HTA encompasses improper BP measurement techniques, white-coat effect, drug-induced HTA, secondary HTA, and incorrectness in antihypertensive management, whether due to suboptimal medication or nonadherence to treatment by patients. To define true resistant HTA, it is necessary to confirA adherence to treatment and eliminate potential secondary causes of HTA; otherwise, resistant HTN is merely apparent and termed as pseudoresistant HTA. For patients experiencing resistant HTA, the fourth-line treatment generally involves the use of a mineralocorticoid receptor antagonist (MRA), primarily spironolactone, followed by a beta blocker as the fifth option. The term refractory HTA refers to an ‘extreme phenotype’ of HTA, which is defined by the inability to control BP even when utilizing a regimen of five or more antihypertensive agents, including two of them being a long-acting thiazide-like diuretic and MRA. Acutely elevated BP also represent uncontrolled HTA, with guidelines recognizing at least two forms: moderately severe and extremely severe HTA crisis. The treatment approaches for these two categories differ significantly. We proposed a third category that addresses intermediate risk, which seems to be a logical extension of existing classifications.

  • Open Access

    VENOUS THROMBOEMBOLISM (VTE) OUGHT TO BE DIVIDED INTO DEEP VEIN THROMBOSIS (DVT) AND PULMONARY THROMBOEMBOLISM (PTE), NOT PULMONARY EMBOLISM (PE)

    by Goran Koraćević, Dimitrije Pavlović

    Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE), represents a significant healthcare burden worldwide. Different aspects of clinical conditions underlying different types of embolization are discussed in order to overcome the controversy over current names for these conditions. Therefore, we suggest that venous thromboembolism (VTE) ought to be divided into deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE), not pulmonary embolism (PE).


  • Open Access

    Acute myocardial infarction in patients under forty-five years of age: What has changed in ten years?

    by Danijela Đorđević-Radojković, Miodrag Damjanović, Svetlana Apostolović, Jelena Milošević, Dragana Stanojević, Goran Koraćević, Ružica Janković-Tomašević, Tomislav Kostić, Sonja Dakić, Jelena Cvetković, et al.

    The incidence of acute myocardial infarction (AMI) is declining in developed countries due to better prevention and more effective treatment of risk factors, however, the proportion of younger patients with AMI is increasing. The aim of the research was to compare patients under the age of 45 years with acute myocardial infarction at a ten-year interval, to detect changes in frequency and risk factors of AMI. The retrospective study included patients under the age of 45 years, hospitalized at the Cardiology Clinic, University Clinical Center Niš, with a diagnosis of AMI during 2023 and 2013. The frequency of AMI, risk factors for coronary artery disease, the way of presentation and prevalence of coronary artery disease in both groups were compared. During the ten-year period, the total number of patients annually hospitalized with AMI increased (985 vs 1691). The proportion of younger patients increased significantly from 18 (1.7%) in 2013 to 57 (3.4%) in 2023, p = 0.008. The youngest patient with AMI in 2013 was 31 years old and in 2023, 25 years. The groups differed significantly in average age (43.3 years in 2013 vs 33.2 years in 2023, p = 0.02). Significantly more patients had dyslipidemia (89.8% vs 47.1%) and positive family history (87.8% vs 47.1%) in the 2023 group. The majority of patients in both groups presented with ST-segment elevation myocardial infarction (STEMI) and the majority had single-vessel disease. During 2023, the number of younger patients with three-vessel disease increased (5.3% vs 0%). The proportion of patients aged up to 45 years among patients with AMI in our community has increased over the last ten years, and the average age and the minimum age of this patient group have decreased, with a higher frequency of dyslipidemia, heredity, and three-vessel coronary disease.